Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 02, 2025 10:07 ET | Source: Spherix Global Insights

Access Barriers Hamper Early Line Adoption of UCB’s Bimzelx at Six Months Post-Launch in Psoriatic Arthritis and Axial Spondyloarthritis, According to Spherix Global Insights

EXTON, PA, June 02, 2025 (GLOBE NEWSWIRE) -- Just over six months into its dual launch across Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA), UCB’s Bimzelx (bimekizumab) is...